{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:33Z","timestamp":1707524613111},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"DOI":"10.7759\/cureus.29107","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T12:49:56Z","timestamp":1663073396000},"source":"Crossref","is-referenced-by-count":0,"title":["The Risk of Fatal Arrhythmias in Post-Myocardial Infarction Depression in Association With Venlafaxine"],"prefix":"10.7759","author":[{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsi Krishna","family":"Lavu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana Abdelwahab","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruimin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Potla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushen","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"Al Qabandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitri Aninditha","family":"Nandula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinmayi Sree","family":"Boddepalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960200304","article-title":"Depression and coronary heart disease: a review for cardiologists","volume":"20","author":"Carney RM","year":"1997","unstructured":"Carney RM, Freedland KE, Sheline YI, Weiss ES. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol. 1997, 20:196-200. 10.1002\/clc.4960200304","journal-title":"Clin Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.831359","article-title":"Psychological and psychopharmacological interventions in psychocardiology","volume":"13","author":"Kahl KG","year":"2022","unstructured":"Kahl KG, Stapel B, Correll CU. Psychological and psychopharmacological interventions in psychocardiology. Front Psychiatry. 2022, 13:831359. 10.3389\/fpsyt.2022.831359","journal-title":"Front Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2003.015230","article-title":"Heart and mind: (2) psychotropic and cardiovascular therapeutics","volume":"81","author":"Shah SU","year":"2005","unstructured":"Shah SU, Iqbal Z, White A, White S. Heart and mind: (2) psychotropic and cardiovascular therapeutics. Postgrad Med J. 2005, 81:33-40. 10.1136\/pgmj.2003.015230","journal-title":"Postgrad Med J"},{"key":"ref4","article-title":"Depression and coronary artery disease: the association, mechanisms, and therapeutic implications","volume":"6","author":"Khawaja IS","year":"2009","unstructured":"Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry (Edgmont). 2009, 6:38-51.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3205\/000194","article-title":"Position paper on the importance of psychosocial factors in cardiology: update 2013","volume":"12","author":"Ladwig KH","year":"2014","unstructured":"Ladwig KH, Lederbogen F, Albus C, et al.. Position paper on the importance of psychosocial factors in cardiology: update 2013. Ger Med Sci. 2014, 12:Doc09. 10.3205\/000194","journal-title":"Ger Med Sci"},{"key":"ref6","article-title":"Cardiovascular considerations in antidepressant therapy: an evidence-based review","volume":"8","author":"Yekehtaz H","year":"2013","unstructured":"Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013, 8:169-76.","journal-title":"J Tehran Heart Cent"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S200360","article-title":"Cardiac dysautonomia in depression - heart rate variability biofeedback as a potential add-on therapy","volume":"15","author":"Pinter A","year":"2019","unstructured":"Pinter A, Szatmari S Jr, Horvath T, Penzlin AI, Barlinn K, Siepmann M, Siepmann T. Cardiac dysautonomia in depression - heart rate variability biofeedback as a potential add-on therapy. Neuropsychiatr Dis Treat. 2019, 15:1287-310. 10.2147\/NDT.S200360","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2002.4.1\/pschulz","article-title":"The clinical pharmacology of depressive states","volume":"4","author":"Schulz P","year":"2002","unstructured":"Schulz P, Macher JP. The clinical pharmacology of depressive states. Dialogues Clin Neurosci. 2002, 4:47-56. 10.31887\/DCNS.2002.4.1\/pschulz","journal-title":"Dialogues Clin Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000162","article-title":"Depression and anxiety in heart failure: a review","volume":"26","author":"Celano CM","year":"2018","unstructured":"Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018, 26:175-84. 10.1097\/HRP.0000000000000162","journal-title":"Harv Rev Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13r01511","article-title":"Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature","volume":"15","author":"Rustad JK","year":"2013","unstructured":"Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. Prim Care Companion CNS Disord. 2013, 15:10.4088\/PCC.13r01511","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2014.05.002","article-title":"A systematic approach to pharmacotherapy for geriatric major depression","volume":"30","author":"Mulsant BH","year":"2014","unstructured":"Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014, 30:517-34. 10.1016\/j.cger.2014.05.002","journal-title":"Clin Geriatr Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.595686","article-title":"A consensus statement for safety monitoring guidelines of treatments for major depressive disorder","volume":"45","author":"Dodd S","year":"2011","unstructured":"Dodd S, Malhi GS, Tiller J, et al.. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry. 2011, 45:712-25. 10.3109\/00048674.2011.595686","journal-title":"Aust N Z J Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s6880","article-title":"The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes","volume":"6","author":"Huffman JC","year":"2010","unstructured":"Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat. 2010, 6:123-36. 10.2147\/ndt.s6880","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018686","article-title":"Psychiatric and psychological interventions for depression in patients with heart disease: a scoping review","volume":"9","author":"Zambrano J","year":"2020","unstructured":"Zambrano J, Celano CM, Januzzi JL, Massey CN, Chung WJ, Millstein RA, Huffman JC. Psychiatric and psychological interventions for depression in patients with heart disease: a scoping review. J Am Heart Assoc. 2020, 9:e018686. 10.1161\/JAHA.120.018686","journal-title":"J Am Heart Assoc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001287","article-title":"The effect of venlafaxine on electrocardiogram intervals during treatment for depression in older adults","volume":"40","author":"Behlke LM","year":"2020","unstructured":"Behlke LM, Lenze EJ, Pham V, et al.. The effect of venlafaxine on electrocardiogram intervals during treatment for depression in older adults. J Clin Psychopharmacol. 2020, 40:553-9. 10.1097\/JCP.0000000000001287","journal-title":"J Clin Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02849.x","article-title":"Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases","volume":"64","author":"Howell C","year":"2007","unstructured":"Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007, 64:192-7. 10.1111\/j.1365-2125.2007.02849.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03382.x","article-title":"Electrocardiogram changes and arrhythmias in venlafaxine overdose","volume":"67","author":"Isbister GK","year":"2009","unstructured":"Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009, 67:572-6. 10.1111\/j.1365-2125.2009.03382.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37132014000300015","article-title":"Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine","volume":"40","author":"Ferreira PG","year":"2014","unstructured":"Ferreira PG, Costa S, Dias N, Ferreira AJ, Franco F. Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine. J Bras Pneumol. 2014, 40:313-8. 10.1590\/s1806-37132014000300015","journal-title":"J Bras Pneumol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c249","article-title":"Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study","volume":"340","author":"Martinez C","year":"2010","unstructured":"Martinez C, Assimes TL, Mines D, Dell'aniello S, Suissa S. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ. 2010, 340:c249. 10.1136\/bmj.c249","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2478\/intox-2019-0024","article-title":"The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet","volume":"12","author":"Sasv\u00e1riov\u00e1 M","year":"2019","unstructured":"Sasv\u00e1riov\u00e1 M, Mich\u00e1likov\u00e1 D, Kaprinay BT, et al.. The effect of venlafaxine on blood pressure and ECG in rats fed with high-fat-fructose diet. Interdiscip Toxicol. 2019, 12:192-9. 10.2478\/intox-2019-0024","journal-title":"Interdiscip Toxicol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.86928","article-title":"Effects of antidepressants on QT interval in people with mental disorders","volume":"16","author":"Aronow WS","year":"2020","unstructured":"Aronow WS, Shamliyan TA. Effects of antidepressants on QT interval in people with mental disorders. Arch Med Sci. 2020, 16:727-41. 10.5114\/aoms.2019.86928","journal-title":"Arch Med Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03049-x","article-title":"Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany","volume":"77","author":"Elsayed M","year":"2021","unstructured":"Elsayed M, Abdel-Kahaar E, Gahr M, Connemann BJ, Denkinger M, Sch\u00f6nfeldt-Lecuona C. Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. Eur J Clin Pharmacol. 2021, 77:767-75. 10.1007\/s00228-020-03049-x","journal-title":"Eur J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383872","article-title":"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?","volume":"10","author":"Pacher P","year":"2004","unstructured":"Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des. 2004, 10:2463-75. 10.2174\/1381612043383872","journal-title":"Curr Pharm Des"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016627","article-title":"Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort","volume":"7","author":"Coughtrie AL","year":"2017","unstructured":"Coughtrie AL, Behr ER, Layton D, Marshall V, Camm AJ, Shakir SA. Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 2017, 7:e016627. 10.1136\/bmjopen-2017-016627","journal-title":"BMJ Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28804","article-title":"Clinical use of antidepressant therapy and associated cardiovascular risk","volume":"4","author":"Waring WS","year":"2012","unstructured":"Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf. 2012, 4:93-101. 10.2147\/DHPS.S28804","journal-title":"Drug Healthc Patient Saf"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2181","article-title":"Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia","volume":"20","author":"Leonard CE","year":"2011","unstructured":"Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf. 2011, 20:903-13. 10.1002\/pds.2181","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v5.i6.175","article-title":"Mechanisms of drug-induced proarrhythmia in clinical practice","volume":"5","author":"Konstantopoulou A","year":"2013","unstructured":"Konstantopoulou A, Tsikrikas S, Asvestas D, Korantzopoulos P, Letsas KP. Mechanisms of drug-induced proarrhythmia in clinical practice. World J Cardiol. 2013, 5:175-85. 10.4330\/wjc.v5.i6.175","journal-title":"World J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2018.29.2","article-title":"Mechanisms underlying the actions of antidepressant and antipsychotic drugs that cause sudden cardiac arrest","volume":"7","author":"Sicouri S","year":"2018","unstructured":"Sicouri S, Antzelevitch C. Mechanisms underlying the actions of antidepressant and antipsychotic drugs that cause sudden cardiac arrest. Arrhythm Electrophysiol Rev. 2018, 7:199-209. 10.15420\/aer.2018.29.2","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.2.181","article-title":"Sudden cardiac death secondary to antidepressant and antipsychotic drugs","volume":"7","author":"Sicouri S","year":"2008","unstructured":"Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf. 2008, 7:181-94. 10.1517\/14740338.7.2.181","journal-title":"Expert Opin Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.728576","article-title":"Cardiovascular effects of noncardiovascular drugs","volume":"120","author":"Raj SR","year":"2009","unstructured":"Raj SR, Stein CM, Saavedra PJ, Roden DM. Cardiovascular effects of noncardiovascular drugs. Circulation. 2009, 120:1123-32. 10.1161\/CIRCULATIONAHA.107.728576","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/med.21476","article-title":"Comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka P","year":"2018","unstructured":"Mlad\u011bnka P, Applov\u00e1 L, Pato\u010dka J, et al.. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018, 38:1332-403. 10.1002\/med.21476","journal-title":"Med Res Rev"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100216","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina P","year":"2021","unstructured":"Mamoshina P, Rodriguez B, Bueno-Orovio A. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep Med. 2021, 2:100216. 10.1016\/j.xcrm.2021.100216","journal-title":"Cell Rep Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.840452","article-title":"Associations of antidepressants with atrial fibrillation and ventricular arrhythmias\u00a0: a systematic review and meta-analysis","volume":"9","author":"Cao Y","year":"2022","unstructured":"Cao Y, Zhou M, Guo H, Zhu W. Associations of antidepressants with atrial fibrillation and ventricular arrhythmias\u00a0: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:840452. 10.3389\/fcvm.2022.840452","journal-title":"Front Cardiovasc Med"},{"key":"ref34","article-title":"Antidepressants and cardiovascular adverse events: A narrative review","volume":"11","author":"Nezafati MH","year":"2015","unstructured":"Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atheroscler. 2015, 11:295-304.","journal-title":"ARYA Atheroscler"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-016-0053-1","article-title":"Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials","volume":"17","author":"Wi\u015bniowska B","year":"2016","unstructured":"Wi\u015bniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016, 17:12. 10.1186\/s40360-016-0053-1","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs351","article-title":"Drug-induced arrhythmia: pharmacogenomic prescribing?","volume":"34","author":"Behr ER","year":"2013","unstructured":"Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing?. Eur Heart J. 2013, 34:89-95. 10.1093\/eurheartj\/ehs351","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12040","article-title":"Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice","volume":"76","author":"Isbister GK","year":"2013","unstructured":"Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. Br J Clin Pharmacol. 2013, 76:48-57. 10.1111\/bcp.12040","journal-title":"Br J Clin Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012503","article-title":"Association of antidepressant medication type with the incidence of cardiovascular disease in the ARIC study","volume":"8","author":"Almuwaqqat Z","year":"2019","unstructured":"Almuwaqqat Z, Jokhadar M, Norby FL, et al.. Association of antidepressant medication type with the incidence of cardiovascular disease in the ARIC study. J Am Heart Assoc. 2019, 8:e012503. 10.1161\/JAHA.119.012503","journal-title":"J Am Heart Assoc"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12829","article-title":"Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study","volume":"81","author":"Danielsson B","year":"2016","unstructured":"Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol. 2016, 81:773-83. 10.1111\/bcp.12829","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.166619","article-title":"QT prolongation and torsades de pointes with psychotropic agents","volume":"57","author":"Desai N","year":"2015","unstructured":"Desai N, Venkatesh CR, Kumar SS. QT prolongation and torsades de pointes with psychotropic agents. Indian J Psychiatry. 2015, 57:305-8. 10.4103\/0019-5545.166619","journal-title":"Indian J Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2011.0687","article-title":"QTc prolongation by psychotropic drugs and the risk of torsade de pointes","volume":"108","author":"Wenzel-Seifert K","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011, 108:687-93. 10.3238\/arztebl.2011.0687","journal-title":"Dtsch Arztebl Int"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L031","article-title":"Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy","volume":"42","author":"Colucci VJ","year":"2008","unstructured":"Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother. 2008, 42:882-7. 10.1345\/aph.1L031","journal-title":"Ann Pharmacother"},{"key":"ref43","article-title":"Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes","volume":"291","author":"Khalifa M","year":"1999","unstructured":"Khalifa M, Daleau P, Turgeon aJ. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999, 291:280-4.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref44","article-title":"Anti-depressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes","volume":"7","author":"Sala M","year":"2006","unstructured":"Sala M, Coppa F, Cappucciati C, et al.. Anti-depressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs. 2006, 7:256-63.","journal-title":"Curr Opin Investig Drugs"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1089\/ther.2014.0030","article-title":"Successful use of therapeutic hypothermia after cardiac arrest due to amitriptyline and venlafaxine intoxication","volume":"5","author":"Kontio T","year":"2015","unstructured":"Kontio T, Salo A, Kantola T, Toivonen L, Skrifvars MB. Successful use of therapeutic hypothermia after cardiac arrest due to amitriptyline and venlafaxine intoxication. Ther Hypothermia Temp Manag. 2015, 5:104-9. 10.1089\/ther.2014.0030","journal-title":"Ther Hypothermia Temp Manag"},{"key":"ref46","article-title":"Multifactorial QT interval prolongation","volume":"17","author":"Digby G","year":"2010","unstructured":"Digby G, Machaalany J, Malik P, Methot M, Simpson CS, Redfearn D, Baranchuk A.. Multifactorial QT interval prolongation. Cardiol J. 2010, 17:184-8.","journal-title":"Cardiol J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2005.03.065","article-title":"QT interval prolongation associated with venlafaxine administration","volume":"109","author":"Letsas K","year":"2006","unstructured":"Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006, 109:116-7. 10.1016\/j.ijcard.2005.03.065","journal-title":"Int J Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S157708","article-title":"Drug-drug interactions involving antidepressants: focus on desvenlafaxine","volume":"14","author":"Low Y","year":"2018","unstructured":"Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018, 14:567-80. 10.2147\/NDT.S157708","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312472890","article-title":"A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose","volume":"3","author":"Taylor D","year":"2013","unstructured":"Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013, 3:151-61. 10.1177\/2045125312472890","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103400-the-risk-of-fatal-arrhythmias-in-post-myocardial-infarction-depression-in-association-with-venlafaxine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:25Z","timestamp":1707508045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103400-the-risk-of-fatal-arrhythmias-in-post-myocardial-infarction-depression-in-association-with-venlafaxine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.29107","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}